GB9907461D0 - Neurite regeneration - Google Patents

Neurite regeneration

Info

Publication number
GB9907461D0
GB9907461D0 GBGB9907461.9A GB9907461A GB9907461D0 GB 9907461 D0 GB9907461 D0 GB 9907461D0 GB 9907461 A GB9907461 A GB 9907461A GB 9907461 D0 GB9907461 D0 GB 9907461D0
Authority
GB
United Kingdom
Prior art keywords
neurite regeneration
neurite
regeneration
rar22
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9907461.9A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kings College London
Original Assignee
Kings College London
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kings College London filed Critical Kings College London
Priority to GBGB9907461.9A priority Critical patent/GB9907461D0/en
Publication of GB9907461D0 publication Critical patent/GB9907461D0/en
Priority to AU39755/00A priority patent/AU770394B2/en
Priority to GB0123381A priority patent/GB2365772A/en
Priority to PCT/GB2000/001211 priority patent/WO2000057900A2/en
Priority to DE60031396T priority patent/DE60031396T2/de
Priority to AT00918991T priority patent/ATE342728T1/de
Priority to CA002369009A priority patent/CA2369009A1/en
Priority to KR1020017012263A priority patent/KR20010104401A/ko
Priority to EP00918991A priority patent/EP1180039B1/en
Priority to EP06076367A priority patent/EP1762243A1/en
Priority to CNB008080887A priority patent/CN100350970C/zh
Priority to JP2000607650A priority patent/JP2002540164A/ja
Priority to US10/838,906 priority patent/US20040266715A1/en
Priority to US11/526,458 priority patent/US20070054961A1/en
Priority to US11/583,427 priority patent/US20070213290A1/en
Priority to US12/570,659 priority patent/US20100317109A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1783—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • High Energy & Nuclear Physics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
GBGB9907461.9A 1996-10-17 1999-03-31 Neurite regeneration Ceased GB9907461D0 (en)

Priority Applications (16)

Application Number Priority Date Filing Date Title
GBGB9907461.9A GB9907461D0 (en) 1999-03-31 1999-03-31 Neurite regeneration
JP2000607650A JP2002540164A (ja) 1999-03-31 2000-03-30 因 子
CA002369009A CA2369009A1 (en) 1999-03-31 2000-03-30 Factor for regulation of neurite growth
EP00918991A EP1180039B1 (en) 1999-03-31 2000-03-30 Composition for the treatment of a neurological disorder
PCT/GB2000/001211 WO2000057900A2 (en) 1999-03-31 2000-03-30 Factor for regulation of neurite growth
DE60031396T DE60031396T2 (de) 1999-03-31 2000-03-30 Zubereitung zur behandlung einer neurologischen erkrankung
AT00918991T ATE342728T1 (de) 1999-03-31 2000-03-30 Zubereitung zur behandlung von einer neurologischen erkrankung
AU39755/00A AU770394B2 (en) 1999-03-31 2000-03-30 Factor
KR1020017012263A KR20010104401A (ko) 1999-03-31 2000-03-30 인자
GB0123381A GB2365772A (en) 1999-03-31 2000-03-30 Factor
EP06076367A EP1762243A1 (en) 1999-03-31 2000-03-30 Factor for regulation of neurite growth
CNB008080887A CN100350970C (zh) 1999-03-31 2000-03-30 因子
US10/838,906 US20040266715A1 (en) 1999-03-31 2004-05-03 Neurite regeneration
US11/526,458 US20070054961A1 (en) 1999-03-31 2006-09-25 Factor
US11/583,427 US20070213290A1 (en) 1996-10-17 2006-10-19 Neurite regeneration
US12/570,659 US20100317109A1 (en) 1999-03-31 2009-09-30 Factor

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9907461.9A GB9907461D0 (en) 1999-03-31 1999-03-31 Neurite regeneration

Publications (1)

Publication Number Publication Date
GB9907461D0 true GB9907461D0 (en) 1999-05-26

Family

ID=10850746

Family Applications (2)

Application Number Title Priority Date Filing Date
GBGB9907461.9A Ceased GB9907461D0 (en) 1996-10-17 1999-03-31 Neurite regeneration
GB0123381A Withdrawn GB2365772A (en) 1999-03-31 2000-03-30 Factor

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB0123381A Withdrawn GB2365772A (en) 1999-03-31 2000-03-30 Factor

Country Status (11)

Country Link
US (2) US20070054961A1 (https=)
EP (2) EP1180039B1 (https=)
JP (1) JP2002540164A (https=)
KR (1) KR20010104401A (https=)
CN (1) CN100350970C (https=)
AT (1) ATE342728T1 (https=)
AU (1) AU770394B2 (https=)
CA (1) CA2369009A1 (https=)
DE (1) DE60031396T2 (https=)
GB (2) GB9907461D0 (https=)
WO (1) WO2000057900A2 (https=)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60132436T2 (de) * 2000-03-30 2008-04-17 Oxford Biomedica (Uk) Ltd. Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
GB0103998D0 (en) * 2001-02-19 2001-04-04 King S College London Method
US7490472B2 (en) 2003-02-11 2009-02-17 Statoil Asa Efficient combined cycle power plant with CO2 capture and a combustor arrangement with separate flows
EP2931899A1 (en) 2012-12-12 2015-10-21 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
DK2931897T3 (en) 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
MX2015017312A (es) 2013-06-17 2017-04-10 Broad Inst Inc Suministro y uso de composiciones, vectores y sistemas crispr-cas para la modificación dirigida y terapia hepáticas.
KR20250012194A (ko) 2013-06-17 2025-01-23 더 브로드 인스티튜트, 인코퍼레이티드 바이러스 구성성분을 사용하여 장애 및 질환을 표적화하기 위한 crispr-cas 시스템 및 조성물의 전달, 용도 및 치료 적용
KR20160019553A (ko) 2013-06-17 2016-02-19 더 브로드 인스티튜트, 인코퍼레이티드 유사분열 후 세포의 질병 및 장애를 표적화하고 모델링하기 위한 시스템, 방법 및 조성물의 전달, 유전자 조작 및 최적화
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
MX2016007325A (es) 2013-12-12 2017-07-19 Broad Inst Inc Composiciones y metodos de uso de sistemas crispr-cas en desordenes debidos a repeticion de nucleotidos.
AU2014361781B2 (en) 2013-12-12 2021-04-01 Massachusetts Institute Of Technology Delivery, use and therapeutic applications of the CRISPR -Cas systems and compositions for genome editing
BR112016013207A2 (pt) 2013-12-12 2017-09-26 Massachusetts Inst Technology administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais
EP3080259B1 (en) 2013-12-12 2023-02-01 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions with new architectures for sequence manipulation
EP3686279B1 (en) 2014-08-17 2023-01-04 The Broad Institute, Inc. Genome editing using cas9 nickases
WO2016049163A2 (en) 2014-09-24 2016-03-31 The Broad Institute Inc. Use and production of chd8+/- transgenic animals with behavioral phenotypes characteristic of autism spectrum disorder
WO2016049258A2 (en) 2014-09-25 2016-03-31 The Broad Institute Inc. Functional screening with optimized functional crispr-cas systems
EP3889260A1 (en) 2014-12-12 2021-10-06 The Broad Institute, Inc. Protected guide rnas (pgrnas)
WO2016094874A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Escorted and functionalized guides for crispr-cas systems
WO2016094880A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
WO2016094872A1 (en) 2014-12-12 2016-06-16 The Broad Institute Inc. Dead guides for crispr transcription factors
CN107207488B (zh) 2014-12-17 2020-11-17 伦敦皇家学院 作为视黄酸受体β(RARβ)激动剂的双环杂芳基-杂芳基-苯甲酸化合物
EP3234192B1 (en) 2014-12-19 2021-07-14 The Broad Institute, Inc. Unbiased identification of double-strand breaks and genomic rearrangement by genome-wide insert capture sequencing
WO2016106236A1 (en) 2014-12-23 2016-06-30 The Broad Institute Inc. Rna-targeting system
WO2016106244A1 (en) 2014-12-24 2016-06-30 The Broad Institute Inc. Crispr having or associated with destabilization domains
WO2016201368A1 (en) 2015-06-10 2016-12-15 The Broad Institute Inc. Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia
CA3012607A1 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Crispr enzymes and systems
EP4159856A1 (en) 2015-06-18 2023-04-05 The Broad Institute, Inc. Novel crispr enzymes and systems
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
TWI813532B (zh) 2015-06-18 2023-09-01 美商博得學院股份有限公司 降低脱靶效應的ｃｒｉｓｐｒ酶突變
WO2016205745A2 (en) 2015-06-18 2016-12-22 The Broad Institute Inc. Cell sorting
WO2017031370A1 (en) 2015-08-18 2017-02-23 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US12241053B2 (en) 2015-10-09 2025-03-04 The Brigham And Women's Hospital, Inc. Modulation of novel immune checkpoint targets
CN109153980B (zh) 2015-10-22 2023-04-14 布罗德研究所有限公司 Vi-b型crispr酶和系统
EP3368687B1 (en) 2015-10-27 2021-09-29 The Broad Institute, Inc. Compositions and methods for targeting cancer-specific sequence variations
WO2017075465A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting gata3
WO2017075451A1 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by detecting and targeting pou2af1
WO2017075478A2 (en) 2015-10-28 2017-05-04 The Broad Institute Inc. Compositions and methods for evaluating and modulating immune responses by use of immune cell gene signatures
WO2017106657A1 (en) 2015-12-18 2017-06-22 The Broad Institute Inc. Novel crispr enzymes and systems
CN110382692A (zh) 2016-04-19 2019-10-25 博德研究所 新型crispr酶以及系统
US20200263190A1 (en) 2016-04-19 2020-08-20 The Broad Institute, Inc. Novel crispr enzymes and systems
EP3445853A1 (en) 2016-04-19 2019-02-27 The Broad Institute, Inc. Cpf1 complexes with reduced indel activity
CA3028158A1 (en) 2016-06-17 2017-12-21 The Broad Institute, Inc. Type vi crispr orthologs and systems
GB201610867D0 (en) 2016-06-22 2016-08-03 King S College London Crystalline forms of a therapeutic compound and processes for their preparation
US12595478B2 (en) 2016-06-29 2026-04-07 The Broad Institute, Inc. Crispr-Cas systems having destabilization domain
CN110312799A (zh) 2016-08-17 2019-10-08 博德研究所 新型crispr酶和系统
WO2018035388A1 (en) 2016-08-17 2018-02-22 The Broad Institute, Inc. Novel crispr enzymes and systems
US20190262399A1 (en) 2016-09-07 2019-08-29 The Broad Institute, Inc. Compositions and methods for evaluating and modulating immune responses
WO2018064208A1 (en) 2016-09-28 2018-04-05 The Broad Institute, Inc. Systematic screening and mapping of regulatory elements in non-coding genomic regions, methods, compositions, and applications thereof
US12447213B2 (en) 2016-10-07 2025-10-21 The Broad Institute, Inc. Modulation of novel immune checkpoint targets
ES2950676T3 (es) 2017-01-30 2023-10-11 Kws Saat Se & Co Kgaa Reparación de enlace de plantillas a endonucleasas para modificación de genes
AU2018234825B2 (en) 2017-03-15 2020-12-17 Massachusetts Institute Of Technology Novel CAS13B orthologues CRISPR enzymes and systems
AU2018251801B2 (en) 2017-04-12 2024-11-07 Massachusetts Institute Of Technology Novel type VI CRISPR orthologs and systems
US12350368B2 (en) 2017-04-14 2025-07-08 The Broad Institute, Inc. Delivery of large payloads
US11591601B2 (en) 2017-05-05 2023-02-28 The Broad Institute, Inc. Methods for identification and modification of lncRNA associated with target genotypes and phenotypes
EP3625342B1 (en) 2017-05-18 2022-08-24 The Broad Institute, Inc. Systems, methods, and compositions for targeted nucleic acid editing
WO2019010422A1 (en) 2017-07-07 2019-01-10 The Broad Institute, Inc. ANTIVIRAL THERAPY BASED ON THE CRISPR SYSTEM
JP2020535802A (ja) 2017-09-21 2020-12-10 ザ・ブロード・インスティテュート・インコーポレイテッド 標的化核酸編集のための系、方法、及び組成物
EP3692152B1 (en) 2017-10-04 2025-09-03 The Broad Institute, Inc. Methods and compositions for altering function and structure of chromatin loops and/or domains
US12227742B2 (en) 2017-10-23 2025-02-18 The Broad Institute, Inc. Nucleic acid modifiers
US11547614B2 (en) 2017-10-31 2023-01-10 The Broad Institute, Inc. Methods and compositions for studying cell evolution
WO2019094984A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods for determining spatial and temporal gene expression dynamics during adult neurogenesis in single cells
EP3710039A4 (en) 2017-11-13 2021-08-04 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR TREATMENT OF CANCER BY TARGETING THE CLEC2D-KLRB1 PATH
WO2019126709A1 (en) 2017-12-22 2019-06-27 The Broad Institute, Inc. Cas12b systems, methods, and compositions for targeted dna base editing
US10968257B2 (en) 2018-04-03 2021-04-06 The Broad Institute, Inc. Target recognition motifs and uses thereof
CN113286884A (zh) 2018-08-07 2021-08-20 博德研究所 新型cas12b酶和系统
WO2020041380A1 (en) 2018-08-20 2020-02-27 The Broad Institute, Inc. Methods and compositions for optochemical control of crispr-cas9
CA3124110A1 (en) 2018-12-17 2020-06-25 The Broad Institute, Inc. Crispr-associated transposase systems and methods of use thereof
US12215382B2 (en) 2019-03-01 2025-02-04 The General Hospital Corporation Liver protective MARC variants and uses thereof
US12534714B2 (en) 2019-03-18 2026-01-27 The Broad Institute, Inc. Type VII CRISPR proteins and systems
WO2020236972A2 (en) 2019-05-20 2020-11-26 The Broad Institute, Inc. Non-class i multi-component nucleic acid targeting systems
GB201907647D0 (en) * 2019-05-30 2019-07-17 King S College London Therapeutic methods
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
CN119562762A (zh) 2022-04-04 2025-03-04 加利福尼亚大学董事会 遗传互补组合物和方法
WO2025072383A1 (en) 2023-09-25 2025-04-03 The Broad Institute, Inc. Viral open reading frames, uses thereof, and methods of detecting the same
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025129158A1 (en) 2023-12-15 2025-06-19 The Broad Institute, Inc. Engineered arc delivery vesicles and uses thereof
WO2025250808A1 (en) 2024-05-29 2025-12-04 The Brigham And Women’S Hospital, Inc. Anti-crispr delivery compositions and methods

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
JP2608540B2 (ja) 1982-05-19 1997-05-07 ギスト ブロカデス ナ−ムロ−ゼ フエンノ−トチヤツプ クルイベロミセス種のためのクローニング系
NZ207394A (en) 1983-03-08 1987-03-06 Commw Serum Lab Commission Detecting or determining sequence of amino acids
IE58014B1 (en) 1983-07-06 1993-06-16 Gist Brocades Nv Molecular cloning and expression in industrial microorganism species
US4885249A (en) 1984-12-05 1989-12-05 Allelix, Inc. Aspergillus niger transformation system
DE3650783T2 (de) 1985-04-15 2004-07-15 Dsm Ip Assets B.V. Verwendung des Glucoamylasepromotors aus Apergillus
NO872932L (no) 1986-07-18 1988-01-19 Gist Brocades Nv Fremgangsmaate for fremstilling av proteiner med faktorviiiaktivitet ved hjelp av mikrobielle vertsceller, eksprimeringsvektorer, vertsceller, antibiotika.
HU201870B (en) * 1987-01-16 1991-01-28 Us Health Process for producing pharmaceutical compositions containing isoretinoin as active component
US4808630A (en) * 1987-01-16 1989-02-28 United States Of America Method of treating psychotic illnesses
NO302485B1 (no) 1987-07-28 1998-03-09 Gist Brocades Bv Fremgangsmåte for fremstilling av et polypeptid av interesse i en Klyveromyces vertscelle, transformert Klyveromyces vertscelle og anvendelse derav, plasmid og DNA konstruksjon
KR100225087B1 (ko) 1990-03-23 1999-10-15 한스 발터라벤 피타아제의 식물내 발현
CA2211142A1 (en) * 1995-01-23 1996-08-01 Ligand Pharmaceuticals Incorporated Human retinoid x receptor - gamma (hrxr-gamma)
IT1276459B1 (it) * 1995-06-30 1997-10-31 Khodor Ammar Composizioni cosmetiche con proprieta' antimicotiche, efficaci contro la psoriasi e la caduta dei capelli e metodo cosmetico per la
FR2739557B1 (fr) * 1995-10-09 1997-11-14 Cird Galderma Utilisation d'un ligand agoniste specifique rar-gamma
US5965606A (en) * 1995-12-29 1999-10-12 Allergan Sales, Inc. Methods of treatment with compounds having RAR.sub.α receptor specific or selective activity
WO1998049271A1 (en) 1997-04-25 1998-11-05 American Home Products Corporation Human neuronal cell line
AU1122099A (en) * 1997-10-27 1999-05-17 Curis, Inc. Enhancement of morphogen activity

Also Published As

Publication number Publication date
CN100350970C (zh) 2007-11-28
DE60031396T2 (de) 2007-08-30
DE60031396D1 (de) 2006-11-30
WO2000057900A2 (en) 2000-10-05
US20100317109A1 (en) 2010-12-16
AU770394B2 (en) 2004-02-19
EP1180039A2 (en) 2002-02-20
EP1762243A1 (en) 2007-03-14
KR20010104401A (ko) 2001-11-26
US20070054961A1 (en) 2007-03-08
WO2000057900A3 (en) 2001-02-15
JP2002540164A (ja) 2002-11-26
AU3975500A (en) 2000-10-16
EP1180039B1 (en) 2006-10-18
GB0123381D0 (en) 2001-11-21
CA2369009A1 (en) 2000-10-05
ATE342728T1 (de) 2006-11-15
CN1355706A (zh) 2002-06-26
GB2365772A (en) 2002-02-27

Similar Documents

Publication Publication Date Title
GB9907461D0 (en) Neurite regeneration
IL146119A0 (en) Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics
PL342515A1 (en) Drug administering device
ATE277615T1 (de) Therapeutische zusammensetzungen, enthaltend amlopidin und atorvastatin
NZ513983A (en) Novel cyclic tetrapeptide derivatives and use thereof as drugs
HRP20030046A2 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
PL337277A1 (en) Body care composition
IL137186A0 (en) Device for inhaling medicament
CZ2000522A3 (cs) Farmaceutický prostředek na bázi piperidinalkanolového antihistaminika a použití
CY2482B1 (en) Paroxetine in treatment of depression.
BR9709826A (pt) Artigos absorventes respiráveis
AU2636602A (en) Use of sarp-1 for the treatment and/or prevention of scleroderma
HUP9902883A3 (en) Bis/acridinecarboxamide/ and bis/phenazinecarboxamide/ derivatives as antitumour agents, preparation and use thereof
BG104914A (en) Paroxetine maleate
IT1309104B1 (it) Corpo stampato in resina.
GB9802542D0 (en) New use
HUP0103262A3 (en) Medicament containing platinum complex compounds and the use thereof
AU8561998A (en) Cyclic compounds and medicinal use thereof
GB2380981B (en) Child's push-chairs
GB2336539B (en) Wood treatment
GB9914392D0 (en) Child's push-chairs
GB9923706D0 (en) Sleep E's
SI1189615T1 (en) Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines
ZA986485B (en) Levobupivacaine and its use.
ZA986484B (en) Levobupivacaine and its use.

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)